Stock Taper
SCREENER COMPARE ANY 2 STOCKS
ATXI
AVENUE THERAPEUTICS, INC.
OTC
$0.45
▼ DOWN 21.66% (-0.13)

KEY STATISTICS

Market Cap$1.49 M
52w High$0.97
52w Low$0.15
Dividend Yield—
Frequency—
P/E-0.53
Volume19.68K
Shares Out.3.29M

COMPANY

LEADERSHIP

Alexandra MacLean
CHIEF EXECUTIVE
Alexandra MacLean

COMPENSATION 2026

Salary$420,000
Stock Awards$406,300
Incentive Plan Pay$0
All Other Comp.$13,800
Total$840,100

ABOUT

SECTOR
Healthcare
WENT PUBLIC
June 27, 2017
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
1

PRICE TARGET

Target High$12.00
Target Low$12.00
Target Median$12.00
Target Consensus$12.00

UPCOMING EARNINGS

DateNov 13, 2026
DayFriday
Rev. Est.—
NOV
13
FRI

SPLIT RECORD

DATETYPERATIO
2024-04-26Reverse1:75
2022-09-23Reverse1:15

PRICE

$0.45 ▼ DOWN 21.66% (−$0.13)
OVERLAYS
$0.43$0.45$0.4710:14 AM10:35 AM10:55 AM11:16 AM11:37 AM11:57 AM12:18 PM0.45

About Avenue Therapeutics, Inc.

https://www.avenuetx.com ↗

Avenue Therapeutics, Inc. is a New York-based specialty pharma developing intravenous Tramadol for acute pain, currently in Phase III trials for post-operative pain.

INDUSTRY

Biotechnology

A SERVICE AVENUE THERAPEUTICS, INC. IS KNOWN FOR

IV Tramadol

IV Tramadol is a late-stage clinical intravenous analgesic for postoperative pain, with FDA agreement for Phase 3 safety studies, and is a key development program for Avenue Therapeutics.

COMPETITORS

COMPETITOR
HRTX COMPARE
PCRX COMPARE
VRTX COMPARE

RATINGS SNAPSHOT

Overall rating: C

DCFROEROAD/EP/EP/B
Discounted Cash Flow3
Return On Equity1
Return On Assets1
Debt To Equity1
Price To Earnings1
Price To Book3
Overall Score2

INSIDER TRADES

★
10 PERCENT OWNER
Fortress Biotech, Inc.
Purchase · 111.2K shares
2026-01-02

SECTORS PEERS

PEERPRICE
PALI$2.00COMPARE
UNCY$5.26COMPARE
VRAX$2.85COMPARE
GTBP$0.31COMPARE
ADTX$0.01COMPARE
ENSC$0.40COMPARE
REVB$1.05COMPARE
MTVA$1.70COMPARE